This is a delivery order awarded to Genentech USA, Inc., a biotechnology company that develops and manufactures pharmaceuticals, by the Defense Logistics Agency Troop Support Medical. The contract is for the antiviral medication oseltamivir phosphate, with a potential value of $468,558.18 and a firm fixed price pricing type. The place of performance is Genentech's facility in South San Francisco, California. The contract does not utilize any set-asides. Genentech has extensive experience...
This is a $159,762.84 delivery order contract awarded by the Defense Logistics Agency Troop Support Medical to Genentech USA, Inc. for the supply of the antiviral medication oseltamivir phosphate. The contract has a firm fixed price and a completion date of September 11, 2018. Genentech USA, Inc. is a foreign-owned, for-profit manufacturer of pharmaceutical products, and this order was likely issued against an existing indefinite delivery contract or Federal Supply Schedule to support the...
This $342,870.90 firm fixed-price delivery order was awarded by the Defense Logistics Agency Troop Support Medical to Genentech USA, Inc., a biotechnology company that manufactures pharmaceuticals. The contract is for the antiviral drug oseltamivir phospha and does not utilize any set-aside designation. Genentech has provided a variety of biologic medicines to government agencies through multiple federal contract vehicles, including the Pharmaceuticals and Drugs Federal Supply Schedule. This...
The Department of Defense's Defense Logistics Agency Troop Support Medical awarded a $179,992.80 firm fixed-price delivery order to Genentech USA, Inc. to provide the antiviral medication oseltamivir phosphate. Genentech is a foreign-owned, for-profit manufacturer of pharmaceutical products. This order supports maintaining military medical readiness and was placed against an existing indefinite delivery contract. The contract has a completion date of September 12, 2018 and was awarded on...
This is a $102,842.04 delivery order awarded by the Defense Logistics Agency Troop Support Medical to Genentech USA, Inc., a foreign-owned for-profit biopharmaceutical manufacturer. The order is for the antiviral drug oseltamivir phosphate, with a completion date of September 24, 2019. The contract utilizes a firm-fixed price pricing arrangement and has no set-aside designation. Genentech has previously supplied pharmaceuticals such as Tamiflu and Activase to federal agencies including the...
This is a federal delivery order awarded by the Defense Logistics Agency (DLA) to Genentech USA, Inc., a foreign-owned, for-profit biotechnology company. The $93,573.18 firm-fixed-price contract is for the delivery of oseltamivir phosphate, an antiviral medication. The award falls under a larger indefinite delivery contract between Genentech and DLA valued at $27.9 million to supply medical supplies and critical pharmaceuticals for the Department of Defense. No set-aside designation was used....
This is a $112,687.80 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Genentech USA, Inc., a foreign-owned, for-profit pharmaceutical manufacturer, for the supply of oseltamivir phosphate, an antiviral medication. The contract is not designated as a set-aside. Genentech holds several key contract vehicles with federal agencies, including a $4.9 billion Federal Supply Schedule with the Department of Veterans Affairs for pharmaceutical products, and a...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to Genentech USA, Inc., a foreign-owned, for-profit manufacturer of pharmaceuticals and biologics. The contract is for the supply of oseltamivir phosphate, an antiviral medication, with a total ceiling value of $259,393.47. The contract is a firm-fixed price delivery order with a completion date of September 20, 2017. Genentech is the prime contractor, and no major subcontractors were identified. The contract is...
This is a firm fixed-price delivery order contract awarded by the Medical Supply Chain, a component of the Department of Defense, to Genentech USA, Inc. The contract has a ceiling value of $353,101.26 and is for the delivery of oseltamivir phosphate, an antiviral medication. The contract was awarded under a larger federal supply schedule contract between Genentech and the Department of Veterans Affairs, valued at $4.9 billion, that enables the company to efficiently provide pharmaceuticals and...
This federal contract award, SPE2DP16D0008|0021, was made by the Medical Supply Chain division of the Defense agency to Genentech USA, Inc., a foreign-owned, for-profit manufacturer of pharmaceuticals. The $101,188.26 firm-fixed-price delivery order is for the antiviral medication oseltamivir phosphate, with a performance period ending on September 22, 2017. The award is not associated with a set-aside program. Genentech USA, Inc. is a major supplier of pharmaceuticals and biologics to federal...